What is Leerink Partnrs’ Estimate for INSP FY2026 Earnings?

Inspire Medical Systems, Inc. (NYSE:INSP) – Leerink Partnrs decreased their FY2026 earnings estimates for shares of Inspire Medical Systems in a report issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn $1.61 per share for the year, down from their prior estimate of $1.88. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $2.16 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ FY2029 earnings at $5.07 EPS.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.23. The business had revenue of $217.09 million during the quarter, compared to analysts’ expectations of $214.50 million. Inspire Medical Systems had a net margin of 6.17% and a return on equity of 10.38%. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.32 EPS. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS.

Several other equities research analysts have also recently weighed in on INSP. UBS Group set a $89.00 target price on Inspire Medical Systems and gave the stock a “neutral” rating in a research note on Monday, September 22nd. Stifel Nicolaus set a $140.00 price objective on shares of Inspire Medical Systems and gave the stock a “hold” rating in a research report on Tuesday, August 5th. JPMorgan Chase & Co. downgraded shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $195.00 to $110.00 in a research report on Tuesday, August 5th. Piper Sandler reduced their price target on shares of Inspire Medical Systems from $233.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, August 5th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Inspire Medical Systems in a research note on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $148.00.

Inspire Medical Systems Stock Performance

NYSE:INSP opened at $78.92 on Wednesday. The stock has a 50-day simple moving average of $82.86 and a 200-day simple moving average of $120.11. The stock has a market cap of $2.33 billion, a P/E ratio of 45.62, a P/E/G ratio of 2.46 and a beta of 1.16. Inspire Medical Systems has a 1 year low of $70.77 and a 1 year high of $216.01.

Hedge Funds Weigh In On Inspire Medical Systems

A number of hedge funds and other institutional investors have recently made changes to their positions in INSP. Quarry LP raised its stake in Inspire Medical Systems by 2,127.3% during the 1st quarter. Quarry LP now owns 245 shares of the company’s stock valued at $39,000 after acquiring an additional 234 shares during the last quarter. Banque Transatlantique SA purchased a new position in Inspire Medical Systems during the 1st quarter worth $46,000. Daiwa Securities Group Inc. boosted its holdings in shares of Inspire Medical Systems by 38.7% in the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 130 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Inspire Medical Systems by 27.2% during the first quarter. Smartleaf Asset Management LLC now owns 454 shares of the company’s stock worth $71,000 after acquiring an additional 97 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in Inspire Medical Systems by 14.6% in the second quarter. Farther Finance Advisors LLC now owns 603 shares of the company’s stock valued at $78,000 after purchasing an additional 77 shares during the period. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, CFO Richard Buchholz sold 11,000 shares of Inspire Medical Systems stock in a transaction on Friday, August 29th. The shares were sold at an average price of $93.39, for a total value of $1,027,290.00. Following the transaction, the chief financial officer directly owned 44,867 shares in the company, valued at approximately $4,190,129.13. The trade was a 19.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

Inspire Medical Systems declared that its board has initiated a stock buyback program on Monday, August 11th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 8.6% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its stock is undervalued.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.